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ABSTRACT
Rad9 is conserved from yeast to humans and plays
roles in DNA repair (homologous recombination
repair, and base-pair excision repair) and cell cycle
checkpoint controls. It has not previously been
reported whether Rad9 is involved in DNA mismatch
repair (MMR). In this study, we have demonstrated
that both human and mouse Rad9 interacts physi-
cally with the MMR protein MLH1. Disruption of the
interaction by a single-point mutation in Rad9 leads
to significantly reduced MMR activity. This disrup-
tion does not affect S/M checkpoint control and the
first round of G2/M checkpoint control, nor does it
alter cell sensitivity to UV light, gamma rays or
hydroxyurea. Our data indicate that Rad9 is an
important factor in MMR and carries out its MMR
function specifically through interaction with MLH1.
INTRODUCTION
Errors and damage of genomic DNA occur during normal
cellular activities or when cells are exposed to genotoxins.
Cells manage DNA errors and damage using an intricate
network consisting of many proteins including cell cycle
checkpoint proteins and DNA repair factors. The main
DNA repair mechanisms include homologous recombina-
tion (HR), nonhomologous end-joining, base excision,
nucleotide excision, direct reversal and mismatch repair
(MMR) (1,2). When DNA is damaged, the progress of
cells through the cell cycle is arrested or slowed down to
allow time for DNA repair (2,3). Cell cycle checkpoint
proteins Rad9, Rad1 and Hus1 play important roles in
both cell cycle checkpoint control and DNA repair
(2,4,5). These three proteins are evolutionarily conserved
in eukaryotes, and can form a ring-shaped heterotrimer,
dubbed the 9-1-1 complex (6–11). The deletion of each of
the three genes for these proteins in the ﬁssion yeast
Schizosaccharomyces pombe inactivates S/M, intra-S and
G2/M checkpoint controls, and sensitizes ﬁssion yeast cells
to killing by UV light, g-rays and the replication inhibitor
hydroxyurea (HU) (12–15). Disruption of the mouse
ortholog of Rad9 or Hus1 also sensitizes mouse cells to
UV light, g-rays and HU, and leads to genome instability
(16,17).
MMR is an important repair mechanism that maintains
genomic stability. It plays key roles in the repair of base–
base mismatches and insertion/deletion mispairs generated
during DNA replication and recombination. MMR also
functions in preventing HR and in DNA damage signaling
in eukaryotic cells (18–21). In vitro reconstitution bio-
chemical studies indicate that MutS, MutL, RPA,
EXOI, HMGB1, PCNA, replication factor C (RFC),
polymerase and DNA ligase I play important roles in
MMR (22–24). EXOI is only partially responsible for exci-
sion enzyme activity in MMR (25,26). A recent study
showed that regulatory factor X has a stimulatory role
in mismatch-dependent 50 to 30 excision activity (27).
hMRE11 was found to play a role in mismatch-dependent
30 to 50 excision (28). Furthermore, the excision of recon-
stituted MMR proteins is less speciﬁc than in cell extracts,
suggesting that one or more additional regulatory factors
are required for the accuracy of the excision step (22,29).
Therefore, other protein components are required for
MMR to work eﬃciently and accurately under various
in vivo conditions.
In this study, Rad9 was found to physically interact with
mammalian MLH1, a protein essential for DNA MMR.
A single amino acid residue mutation (S160A) on
Rad9 drastically weakened its interaction with MLH1
and cellular mismatch repair activity. The mutation did
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HU, and neither S/M or G2/M checkpoint controls, the
typical phenotypes of Rad9-deleted cells (17), suggesting
that Rad9 functions in MMR speciﬁcally through its
interaction with MLH1.
MATERIALS AND METHODS
Antibodies
Anti-hRad9 polyclonal antibody was obtained by immu-
nizing mice with puriﬁed MBP-hRad9 protein. Anti-
hMLH1 monoclonal antibody (554073) was from BD
Biosciences Pharmingen, monoclonal anti-His antibody,
monoclonal anti-FLAG M2 antibody (F1804), polyclonal
anti-FLAG antibody (F7425) and anti-g-tubulin mono-
clonal antibody were obtained from Sigma–Aldrich, and
anti-HA antibody was obtained from Santa Cruz
Technology.
Cell culture
Human HeLa and HEK 293T cells were cultured in
DMEM (Invitrogen, CA) supplemented with 10% fetal
bovine serum (Hyclone) and 100U/ml penicillin/strepto-
mycin. The 293T cells stably expressing FLAG-hRad9
constructed in our laboratory were cultured in DMEM
with 10% FBS and 50mg/ml Hygromycin B to keep the
plasmid pFLAG-CMV2-hRad9 in the cells.
Methyl methanesulfonate (MMS) and N-nitroso-N-
methylurea (MNU), the alkylation agents for cell treat-
ments were purchased from Sigma–Aldrich (St. Louis,
MO). After HeLa cells reached 80% conﬂuence and
were rinsed twice with PBS, the cells were incubated
with designated concentrations of MMS or MNU for
60min in serum-free DMEM and cells were then har-
vested to prepare lysate for Western blot and co-immuno-
precipitation analysis.
Culture of mouse ES cells was described previously (17).
The antibiotic zeocin, at a ﬁnal concentration of
100mg/ml, was added to cell cultures to select stable trans-
fectants. The selected stable transfectants were cultured in
medium containing 25mg/ml zeocin to maintain the trans-
fected genes in the cells.
Massspectrometry
FLAG-hRad9 was immmunopuriﬁed from 1 10
8 293T
cells stably expressing FLAG-hRad9 using 200ml anti-
FLAG M2 agarose (Sigma). After extensive washings
with lysis buﬀer (150mM NaCl, 50mM Tris–HCl, pH
7.5, 10% glycerol, 0.5% NP-40) containing a protease
inhibitor cocktail (Roche, Indianapolis, IN), the bound
proteins were eluted with 200mg/ml FLAG peptide
(Sigma) in PBS. Eluted proteins were resolved by SDS–
PAGE and revealed by Coomassie blue staining or silver
staining. The apparent bands were excised, in-gel digested
with trypsin, and analyzed by LC-MS/MS on a
ProteomeX-LTQ mass spectrometer (Thermo Fisher
Scientiﬁc, Waltham, USA) to identify the protein bands.
Co-immunoprecipitation
Two vectors, pCDNA3-6HA (30) and pFLAG-CMV2
(Sigma, St Louis, MO), were used to construct plasmids
capable of expressing hMLH1 in human cells. To make
pCDNA3-6HA-hMLH1, pFLAG-CMV2-hMLH1, the
cDNA of the hMLH1 gene was ampliﬁed by PCR from
the plasmid pEGFP-hMLH1 (a kind gift from Dr. Lene
Juel Rasmussen, Roskilde University, Denmark). The
sequences of forward and reverse primers for these PCR
reactions are given in Table 1. The hMLH1 gene was
cloned between the EcoRI and BamHI sites of pFLAG-
CMV2, and in the EcoRI site of pCDNA3-6HA. The
pCDNA3-6HA and pFLAG-CMV2 constructs bearing
the Hus1, Rad1 or Rad9 open reading frame were con-
structed previously (30).
Human embryonic kidney 293T cells were transfected
with the plasmids of interest using Lipofectamine plus
(Invitrogen, USA). Cells were grown to 60–80% conﬂu-
ence in 60mm tissue culture dishes and transfected with
1.5mg pFLAG-CMV2 DNA and 1.5mg pCDNA3-6HA
DNA following the procedure described by Invitrogen.
Table 1. Primers used to amplify cDNA for constructing plasmids
Plasmids Primer Restriction sites
pFLAG-CMV2-hMLH1 50-ATACGCGAATTCATCGTTCGTGGCAGGGGTTAT-30 EcoRI
50-ATACGCGGATCCTTAACACCTCTCAAAGACTT-30 BamHI
pCDNA3-6HA-hMLH1 50-ATACGCGAATTCTCGTTCGTGGCAGGGGT-30 EcoRI
50-ATACGCGAATTCTTAACACCTCTCAAAGAC-30 EcoRI
pCDNA3-6HA-hRad9 50-ATACCCCTCGAGAAGTGCCTGGTCACGGGCGG-30 XhoI
(1-270) 50GCGCGCGGATCCCTACGAGTCGGTGTCTGAGAGTG-30 XhoI
pCDNA3-6HA-hRad9 50-ATACCCGAATTCCACTCCCAGGACCTGGGCTC-30 EcoRI
(271-391) 50-GCGCGCGGATCCTCAGCCTTCACCCTCACTGT-30 EcoRI
pGEX-6P-1-hRad9 50-ATACCCCTCGAGAAGTGCCTGGTCACGGGCGG-30 XhoI
(1-130) 50-ATACCCCTCGAGCTCACAGTCCTGGAAGGACA-30 XhoI
pGEX-6P-1-hRad9 50-ATACCCCTCGAGTCCCTGCAGGCCGTCTTCGA-30 XhoI
(131-270) 50-ATACCCCTCGAGCTAGTGCGAGTCGGTGTCTGAGA-30 XhoI
pGEX-6P-1-hRad9 50-ATTCGGCTCGAGCCTGCACTGGCTG-30 XhoI
(161-270) 50-ATACCCCTCGAGCTAGTGCGAGTCGGTGTCTGAGA-30 XhoI
R9160A-F 50-GCTGTTCTGCCCTTCGCTCCTGCACTGGCTG-30
R9160A-R 50-CAGCCAGTGCAGGAGCGAAGGGCAGAACAGC-30
PET24a (+)-mMLH1 50-ATTCGCGGATCCATGGCGTTTGTAGCAGGAGT-30 BamHI
50-ATACGC GAATTCTTAACACCGCTCAAAGACTT-30 EcoRI
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Constructionof the hRad9S160A mutant
pGEX-6P-1-hRad9 (S160A) was derived from pGEX-6P-
1-hRad9 following the QuickChange mutagenesis proce-
dure (Stratagene). The primers for the mutagenesis PCR
of S160A were R9160A-F and R9160A-R in Table 1. The
mutant was conﬁrmed by DNA sequencing. The plasmid
of pZeoSV2- hRad9 (S160A) was constructed by cutting
from pGEX-6P-1-hRad9 (S160A) and inserting into the
XhoI site of pZeoSV2 (Invitrogen, USA).
Invitro pull-down tests
The full-length hRad9 cDNA removed from pCDNA3-
6HA-hRad9 using XhoI was inserted into the XhoI site
of pGEX-6P-1 (GE Health) to make pGEX-6P-1-hRad9.
The hMLH1 open reading frame was cut from pCDNA3-
6HA-hMLH1 using EcoRI and inserted into the EcoRI
site of pET24a (+) (Novagen) to make pET24a (+)-
hMLH1, and inserted in pGEX-6P-1 to make pGEX-6P-
1-hMLH1. The truncated hRad9 and hMLH1 constructs
were ampliﬁed by PCR using template pGEX-6P-1-
hRad9. The primers are listed in Table 1. The PCR pro-
ducts of hRad9 were digested with XhoI and ligated with
XhoI-digested pGEX-6P-1 to yield pGEX-6P-1-hRad9
plasmids containing hRad9 (1–130), hRad9 (131–270)
and hRad9 (161–270). The pGEX-6P-1-hRad9 (1–270)
and pGEX-6P-1-hRad9 (271–391) plasmids were derived
from pCDNA3-6HA-hRad9 (1–270) and pCDNA3-6HA-
hRad9 (271–391) in the same way as described above.
Cloned sequences were conﬁrmed by DNA sequencing.
Mouse MLH1 cDNA was ampliﬁed from mouse ES cell
cDNA and inserted into BamHI and EcoRI sites of
pET24a (+) to make pET24a (+)-mMLH1.
For the expression of GST tagged hRad9 fragments and
His-hMLH1, Rosetta cells (Invitrogen) harboring expres-
sion plasmids were cultured in LB broth containing
100mg/ml of ampicillin for GST tagged proteins or
50mg/ml of kanamycin for His-hMLH1at 378C. Protein
expression was induced at an A600 of 0.6 by the addition of
isopropytlthiogalactoside (IPTG) to a ﬁnal concentration
of 0.4mM and cells were grown at 168C for 24h and then
harvested. The cell paste, from a 500-ml culture, was
resuspended in 10ml PBS containing 1mM PMSF
at 48C. After sonication, the solution was centrifuged at
16000g for 30min and the supernatant was saved.
For puriﬁcation of the GST tagged protein, 1ml of a
50% slurry of glutathione-Sepharose 4B (GE Healthcare)
in PBS buﬀer with 1% Triton X-100 was added to 10ml
supernatant and incubated overnight at 48C. The GST-
tagged proteins bound to the beads were pelleted at
500g for 5min and washed three times with 1ml PBS
buﬀer containing 1% Triton X-100 and then eluted with
10mM reduced L-glutathione in 50mM Tris–HCl, pH8.0.
To purify His-hMLH1, the supernatant was added to
a 50% slurry of Ni Sepharose High Performance
(Amersham Biosciences) and eluted in a stepwise manner
with 1.6ml (0.4ml 4 times each) of 10, 25, 50, 100
and 250mM imidazole in 50mM Na-phosphate buﬀer,
pH 7.5.
His-tagged hMLH1 expressed in Rosetta cells was
added to the appropriate GST-tagged proteins (100ng)
immobilized on glutathione-Sepharose 4B and incubated
for 1h in 500ml binding buﬀer (50mM Tris–HCl, pH 7.5,
150mM NaCl, 10mM MgCl2, 10% glycerol, 1% Triton
X-100, 0.5mM DTT, 1% BSA) at 48C. After centrifuga-
tion at 500g for 5min, the pellets were washed ﬁve times
with 500ml of binding buﬀer at 48C and fractionated on a
10% SDS–polyacrylamide gel. Western blots for hMLH1
were probed with anti-hMLH1 antibody (BD Biosciences
Pharmingen, Franklin Lake, NJ). A control of immobi-
lized GST alone was run concurrently.
Yeast two-hybrid analysis
The matchmaker LexA two-hybrid system from Clontech
was used to determine the interaction of hMLH1 and
hRad9. pLexA and pB42AD plasmids containing the
hRad9 sequence were constructed previously (30). The
full-length coding sequence of hMLH1 was ampliﬁed by
PCR from pACJ112 (a gift from Dr Lene Juel Rasmussen,
Roskilde University, Denmark). The PCR product was
digested with EcoRI and inserted into the EcoRI sites
of pLexA and pB42AD. Yeast two-hybrid analyses were
performed using a previously published procedure (30).
Tests for MMR activity
A method developed by Lei et al. (32) to detect MMR
activity in living cells was used with minor modiﬁcations.
The DNA substrates, homoduplex and heteroduplex
EGFP plasmids, were prepared in the same way as Lei
et al. (32). Lipofectamine reagents (Invitrogen) were
used to transfect DNA into cultured cells. Cells were
plated on 60-mm dishes at a density of 5 10
5 cells/dish.
Transfection was performed the following day according
to the manufacturer’s protocols. Homoduplex or hetero-
duplex EGFP plasmid measuring 0.2mg was co-
transfected with 0.2mg red ﬂuorescent protein (RFP)
expression plasmid pmRFP-C1 (a kind gift from
Dr. Liusheng He, St Jude Children’s Research Hospital,
Memphis, TN, USA). pmRFP-C1 was used to ascertain
that the transfection eﬃciencies of the EGFP plasmids
were comparable. The cells were trypsinized 20h after
transfection, and resuspended in PBS at a concentration
of 5 10
5 cells/ml. 30000 cells were measured for their
ﬂuorescence intensities at wavelengths of 530/30nm
(green) and above 670nm (red) using a FACSCalibur
ﬂow cytometer (Becton Dickinson). MMR activity was
calculated using a formula developed by Lei et al. (32).
HCT116 cells do not express functional hMLH1 and
therefore have an impaired MMR system. HCT116 cells
transfected with pFLAG-CMV2 and pFLAG-CMV2 -
hMLH1 were used as negative and positive MMR con-
trols. Mouse ES cells were transfected in the same way
as described above for HCT116 cells except for the use
of a specialized medium for culture of ES cells (17).
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Mouse ES cells were seeded at various concentrations in
duplicate on gelatinized tissue culture dishes. Sensitivities
to 250mM HU, 254-nm UV light at 10J/m
2 and
60Co
gamma rays at 6Gy were tested as described previously
(17). Survival against MMS and MNU were evaluated by
counting colonies formed with and without mutagen treat-
ment. Cells were incubated for 24h after seeding in dupli-
cated 60-mm dishes and then exposed to various
concentrations of MMS or MNU for 1h at 378Ci na n
incubator. The medium was removed, the cells were rinsed
once with PBS, and fresh medium was added. Colonies
formed after 1 week of growth were stained with Giemsa
and counted. Relative colony formation (%) was
expressed as colonies per treatment level/colonies that
appeared in the control.
The assay for G2/M checkpoint control of mouse ES
cells induced by gamma rays was conducted as described
in a previous study (17). A previously developed method
was utilized to evaluate S/M checkpoint function (33).
Brieﬂy, 1mM HU was added to ES cells when they were
grown to 70% conﬂuence. Cells were incubated at 378C
under 5% CO2 for designated times, then processed and
suspended in PBS. The cells were probed with rabbit
anti-phospho-histone H3 (Upstate)/FITC-conjugated
anti-rabbit antibodies (Jackson ImmunoResearch
Laboratories, INC), and stained with PI followed by
ﬂow cytometric analysis.
RESULTS
hRad9 interactsphysically with hMLH1
Lindsey-Boltz et al. (34) reported that when FLAG tagged
hRad9 expressed in HEK293T cells was puriﬁed with anti-
FLAG agarose, carbamoyl phosphate synthetase/aspar-
tate transcarbamoylase/dihydroorotase (CAD) and
HSP110 were copuriﬁed with hRad9. Since mammalian
Rad9 plays critical roles in multiple formats of DNA
repair and cell cycle checkpoint control, Rad9 is very
likely to interact with other proteins that are important
for DNA repair and cell cycle checkpoint control.
Therefore, we performed a similar but more careful immu-
noprecipitation assay to search for human proteins cap-
able of interacting with hRad9. To enhance the sensitivity
and reduce background noise, we established HEK293T
cell clones stably expressing FLAG-tagged hRad9 and
picked a clone that expressed FLAG-hRad9at a level
lower than the endogenous hRad9 level (data not
shown). The aﬃnity-puriﬁed proteins associated with
FLAG-hRad9 were fractioned by SDS–PAGE and
revealed by silver staining (Figure 1A). The bands of inter-
est which were not seen in the aﬃnity-puriﬁed extracts
Figure 1. hRad9 associates with hMLH1. (A) Silver-staining of hRad9-associated proteins. 293T cells stably expressing FLAG-hRad9 were immu-
noprecipitated with antibody against FLAG M2. Samples were resolved by 10% SDS–PAGE and visualized by silver staining (lane 2). Lane 1 is a
negative control in which the immunoprecipitation was performed in 293T cells stably expressing FLAG-GFP. The bands of interest were cut and
analyzed by a Mass-Spectrometer, hMLH1 (arrow) was identiﬁed to be one of the partners of hRad9. The protein bands of CAD, HSP110, hRad9,
hHus1 and hRad1 are also indicated. (B) Co-immunoprecipitation of hRad9 and hMLH1. In the upper panel, endogenous hRad9 was immuno-
precipitated with an anti-hMLH1 antibody from cell extracts of 10
6 HeLa cells, but not with pre-immune antiserum (lane 2). The immunopreci-
pitated proteins were detected with antibodies against hMLH1 (upper) and hRad9 (lower). Ten percent of the lysate was used for the loading control
and the remaining 90% for co-immunoprecipitation. In the lower panel, endogenous hMLH1 was immunoprecipitated from cell extracts of 10
6 HeLa
cells with an anti-hRad9 antibody (lane 3), but not with pre-immune serum (lane 2). The immunoprecipitated proteins were visualized by western
blot analysis with antibodies against hMLH1 (upper) and hRad9 (lower).
Nucleic Acids Research, 2008, Vol. 36, No. 20 6409from control HEK293T cells stably expressing FLAG-
GFP, were cut out , digested and analyzed with LC-MS/
MS. LC-MS/MS analysis of hRad9-copuriﬁed bands
revealed that besides CAD and HSP110, there were
other proteins not previously reported to interact with
hRad9. As expected, hHus1 and hRad1 were also puriﬁed
together with hRad9. One of these proteins was hMLH1,
a protein essential for DNA MMR. hRad9 has been
reported to interact with several DNA repair proteins
involved in HR repair and base-excision repair (35–45),
but none of the proteins involved in MMR have pre-
viously been found to associate with Rad9. Therefore,
we chose to characterize this interaction and its functional
signiﬁcance further.
To conﬁrm the association of hMLH1 and hRad9
in vivo, co-immunoprecipitation was performed using an
anti-hMLH1 monoclonal antibody or anti-hRad9 poly-
clonal antibodies. hRad9 and hMLH1 were immunopre-
cipitated together from the extracts of HeLa cells by either
the anti-hMLH1 antibody or the anti-hRad9 antibodies,
but not by pre-immune serum (Figure 1B). This result
indicates that hRad9 and hMLH1 are associated together
in cells.
We next determined whether the interaction between
hRad9 and hMLH1 was direct, rather than being
mediated via accessory proteins. GST pull-down was per-
formed to test whether puriﬁed recombinant hRad9 and
hMLH1 could interact directly in vitro. GST-hMLH1
fusion protein bound to glutathione-Sepharose was incu-
bated with puriﬁed His-hRad9 protein. As shown in
Figure 2A, hRad9 could be pulled down by GST-
hMLH1 (lane 3), while hRad9 did not bind to GST
alone (lane 2). Furthermore, a yeast two-hybridization
assay was also performed to assess the interaction of
hRad9 and hMLH1. Co-expression of pLexA-hMLH1
and pB42AD-hRad9 supported yeast growth and turned
colorless X-gal into blue product (Figure 2B), while the
yeast cells containing pLexA-hMLH1 and pB42AD or
pLexA and pB42AD-hRad9 did not grow and remained
colorless. As a positive control, yeast cells bearing pLexA-
hHus1 and pB42AD-hRad9 grew and turned blue as
expected (30). These results again support the idea that
hRad9 interacts with hMLH1 directly. It is noteworthy
that the yeast bearing pLexA-hRad9 and pB42AD-
hMLH1 did not grow and remained colorless, suggesting
that hRad9 and hMLH1 interact physically only when the
protein contact is in the right direction.
hMLH1does notinteract with hRad1and hHus1
Given that hMLH1 interacts with hRad9, we asked
whether hMLH1 interacted with hRad1 and hHus1, the
two other proteins that form a heterotrimer (the 9-1-1
complex) with hRad9 (7–11,30,46–48). A co-immunopre-
cipitation assay showed that overexpressed HA-tagged
hRad1 and hHus1 did not interact with FLAG-tagged
hMLH1, while as a positive control, HA-hRad9 was
found to interact with FLAG-hMLH1 (Figure 3). These
ﬁndings suggest that hMLH1 binds to free hRad9 but not
to hRad9 within the 9-1-1 complex.
Figure 2. hRad9 interacts with hMLH1 directly. (A) GST pull-down
assay. One microgram GST-hMLH1 (lane 3) or an equal amount of
GST alone (lane 2) was immobilized on glutathione-Sepharose and
incubated with puriﬁed His-hRad9 (100ng) in binding buﬀer for 2h
at 48C. The Sepharose was washed ﬁve times with binding buﬀer. The
puriﬁed proteins were subjected to western blot analysis and probed
with the hRad9 antibody. Lane 1 contains 10ng (10% of the total
input) of His-hRad9. Unlike GST (lane 2), GST-hMLH1 (lane 3)
was able to pull down His-hRad9. (B) Interactions of hRad9 and
hMLH1 in a yeast two-hybrid assay. The pairs of two-hybrid recombi-
nant proteins tested in each population of Saccharomyces cerevisiae
EGY48 host cells were arranged as follows: (left) pLexA-gene
1/(right) pB42AD-gene 2. BD-hMLH1 was able to interact speciﬁcally
with AD-hRad9.
Figure 3. hMLH1 is not associated with hRad1 or hHus1. pCDNA3.0-
6HA-hMLH1 (1.5mg) was transfected into 293T cells along with 1.5mg
pFLAG-CMV2-hRad1 (lanes 1 and 4), 1.5mg pFLAG-CMV2-hRad9
(lanes 2 and 5) and 1.5mg pFLAG-CMV2-hHus1 (lanes 3 and 6),
respectively. Ten percent of the lysate was used for the loading control
and the remaining 90% for co-immunoprecipitation. The lysate was
immunoprecipitated with anti-FLAG antibody, and the western blot
membrane was probed with an antibody against HA (upper) and
against FLAG (lower). The anti-FLAG antibody was able to precipi-
tate HA-hMLH1 mediated only by FLAG-hRad9.
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withhMLH1
To investigate which region of the hRad9 protein was
responsible for mediating the interaction with hMLH1, a
series of hRad9 deletion mutants were generated and
tested for their abilities to interact with full-length
hMLH1 in a GST pull-down assay, in which GST-
tagged fragments of hRad9 were immobilized on
glutathione-Sepharose and incubated with His-hMLH1,
and as a negative control, GST alone with His-hMLH1
was included. Experimental results show that the hMLH1-
interacting region of hRad9 is localized to residues
131–160 (Figure 4A and B). To narrow down which of
these amino acid residues was important for the interac-
tion of hRad9 with hMLH1, each of the polar amino acids
on hRad9 in this region was mutated into alanine residues
separately, and the mutants were subjected to a GST pull-
down assay with His-hMLH1 (Figure 4C). We chose to
only mutate polar residues to avoid disrupting the integ-
rity of protein domains in hRad9. The results from the
GST pull-down assay indicate that S160 of hRad9
(marked with a star in Figure 4A) is important for the
interaction, and all the other polar amino acid residues
in the 131–160 region have no or only very minor
impact on the hRad9–hMLH1 interaction (data not
shown). In one of the following sections, we used
mRad9
–/– mouse ES cells to test the functional importance
of hRad9 in MMR, thus we also examined the interaction
between human hRad9 and mouse mMLH1. As with
hMLH1, mouse mMLH1 interacted directly with wild
type hRad9, but not with mutant S160A hRad9
(Figure 4D), suggesting conservation of Rad9–MLH1
interaction from mouse to human.
DNA mismatch-damage stimulates the hRad9–hMLH1
interaction
N-nitroso-N-methylurea (MNU) is an SN1 DNA-
alkylating agent which produces high levels of O
6-methyl-
guanine (O
6-meG) on DNA in cells. The resulting O
6-meG
lesions are recognized and/or repaired by MMR proteins
(49). Methyl methanesulfonate (MMS), a SN2 DNA-
alkylating-agent, produces high levels of N
7-methylgua-
nine (N
7-meG) and N
3-methyladenine (N
3-meA), which
can lead to the formation of promutagenic abasic sites.
MMR pathways also play a role in the repair of MMS-
induced DNA lesions (50,51). To ﬁnd out whether the
activation of DNA MMR inﬂuences the interaction
between hRad9 and hMLH1, we tested whether increases
in cellular DNA lesions incurred by incubating HeLa cells
with MNU and MMS would enhance hRad9–hMLH1
interactions. Indeed, the interaction between hRad9 and
hMLH1 was enhanced by either MNU or MMS treatment
(Figure 5). The protein loading control using 10% lysate
indicates that hRad9 and hMLH1 did not change within
the experimental period, and thus the higher amount of
hRad9 copuriﬁed with hMLH1 was due to higher aﬃnity
in the presence of MMS or MNU. This enhancement of
hMLH1-hRad9 interaction in response to MMS or MNU
treatment implies that the hMLH1–hRad9 interaction is
an important step in MMR.
Rad9-deleted EScells are defective inMMR
To address the question of whether hRad9 acts together
with MLH1 in MMR, an assay using a T:G mismatch-
corrupted start codon in the EGFP gene transfected into
tested cells was performed to quantitatively measure
MMR activity in living cells (32). The T:G mismatch
can be corrected to T:A by MMR, thus MMR activity
can be determined by ﬂow cytometry measuring the
number of EGFP-positive cells and the intensity of
EGFP expression (refer to ‘Materials and methods’ sec-
tion). Lei et al. (32) reported that HCT116 cells did not
express hMLH1 and did not repair the T:G mismatch
Figure 4. Mapping of the hRad9 domain and amino acid residues that
interact with hMLH1. (A) The map schematically illustrates the regions
and amino acid residues of hRad9 that interact with hMLH1. The
results are derived from the experimental data in Figure 4B–D. The
intact hRad9 contains 391 amino acid residues. The point mutation is
marked with a star. ‘+’ stands for positive, ‘—’for negative and ‘#’ for
reduced interactions with hMLH1 or mMLH1. (B) Mapping the hRad9
region that interacted with His-hMLH1. Immobilized GST-hRad9,
GST-hRad9 (1–270), GST-hRad9 (271–390), GST-hRad9 (1–130),
GST-hRad9 (131–270), GST-hRad9 (161–270) and GST-hRad9
(S160A) (1mg in each case) were incubated with 100ng puriﬁed His-
hMLH1 and the western blot was probed with anti-hMLH1 antibody.
A region between 131 and 160 was shown to be essential for hRad9–
hMLH1 interaction, and Ser160 was shown to be critical for the inter-
action. (C) Graphic depiction of the polar amino acid residues in the
131–160 region of hRad9 that were mutated into alanine residues.
Mutated residues are marked with stars. The italic and large sized ‘S’
is used to label the Ser160 that is critical for the hRad9-hMLH1 inter-
action. (D) The hRad9 S160A point mutation also signiﬁcantly reduced
the interaction of human hRad9 with mouse mMLH1. The experimen-
tal procedure was the same as in Figure 4B.
Nucleic Acids Research, 2008, Vol. 36, No. 20 6411eﬃciently, but transfection with hMLH1 into the cells
compensated for the defect, leading to an increased
number of EGFP-positive cells and enhanced intensity
of EGFP expression. We were able to repeat this experi-
ment as a positive control (Figure 6A and B). The MMR
activity reﬂected by EGFP expression eﬃciency in FLAG-
hMLH1-expressing HCT116 cells was 4.7 times that
of parent HCT116 cells containing empty plasmid
pFLAG-CMV2 (Figure 6B). Using this assay, we found
that mRad9-deleted mouse ES cells (mRad9
–/– cells) had a
signiﬁcantly lower MMR activity than wild-type mouse
ES cells (mRad9
+/+ cells), and ectopic expression in
mRad9
–/– ES cells of mRad9at a level comparable to that
in mRad9
+/+ cells (data not shown) restored the MMR
activity to the level of mRad9
+/+ cells (Figure 6A and
C). Ectopic expression of human Rad9 in mRad9
–/– cells
also complemented the loss of MMR activity resulting
from mRad9 deletion (Figure 6A and C). Taken together,
these data demonstrate that Rad9 plays an important role
in MMR in mammalian cells.
The Ser160-mediated hRad9–hMLH1 interaction is
important inMMR activity
The functional signiﬁcance of the interaction between
hRad9 and hMLH1 was tested with the assay described
above. We picked mRad9
–/– cell clones that expressed wild
type hRad9 (3 clones) and Ser160Ala hRad9 (3 clones) at
levels close to the endogenous mRad9 level in mRad9
+/+
cells (data not shown), and compared their MMR activ-
ities with those of mRad9
–/– and mRad9
+/+ cells. Ectopic
expression of wild type hRad9 in mRad9
–/– cells resulted in
dramatically increased MMR activity as shown previously
(Figures 6C and Figure 7), but expression of Ser160Ala
hRad9 only increased MMR activity slightly (Figure 7).
As shown previously, the Ser160Ala mutation severely
demolished the hRad9–mMLH1 interaction (Figure 4).
Taken together, these results suggest that hRad9 functions
in the MMR pathway through its interaction with MLH1.
It has been reported that cells deﬁcient in MMR are
more tolerant to SN1 type DNA methylation agents than
their parental cells (18,19,52–55). To investigate whether
mRad9-deleted mouse ES cells are resistant to such DNA
methylators or not, the ES cells mentioned above were
examined for sensitivity to MNU. As expected,
mRad9
–/– cells were more resistant to MNU than
mRad9
+/+ cells (Figure 8D), consistent with previous stu-
dies (18,19,52–55). On the other hand, mRad9
–/– cells were
more sensitive to MMS than mRad9
+/+ cells (Figure 8E),
this may be due to the fact that MMS is a SN2 type methyl-
ating agent producing far fewer O
6mG adducts (0.3%)
and a greater proportion of N
3mA (10%) and N
7mG
adducts (87%) than SN1 families (56,57). N
3mA (10%)
Figure 5. Interaction between hRad9 and hMLH1 is enhanced in
response to MMS or MNU treatment. (A) hRad9 displays increased
aﬃnity to hMLH1 after MMS treatment. HeLa cells were mock-treated
or treated with 0.005 and 0.01% MMS (g/solution volume) for 1h, and
the lysate was used for protein concentration controls (upper panel)
and immunoprecipitation by anti-hMLH1 antibody (lower panel).
(B) MNU treatment induced the interaction between hRad9 and
hMLH1 in HeLa cells. HeLa cells were exposed to 0, 0.1 and
0.2mM MNU in serum-free medium for 1h. Immunoprecipitation
and western blot analysis protocols were the same as in (A).
Ten percent of the lysate was used for the loading control and the
remaining 90% for co-immunoprecipitation. (C) The interaction
between hRad9 and hMLH1 was signiﬁcantly induced by MMS.
Data were derived from three independent experiments as in (A).
(D) The interaction between hRad9 and hMLH1 was signiﬁcantly
induced by MNU. The relative hRad9 levels were presented as
mean SD from three independent experiments as described in (B).
Asterisk indicates the statistical signiﬁcance (P<0.01) between precipi-
tated hRad9 levels from cells treated or untreated with MMS or MNU.
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7mG adducts are repaired through base-excision
repair pathway (55), so the damage induced by MMS is
repaired mainly by BER rather than by MMR.
In order to conﬁrm whether the S160A mutation of
hRad9 speciﬁcally inﬂuences MMR function, we tested
the eﬀect of the S160A mutation on the known functions
of hRad9, such as sensitivity to HU, 254-nm UV light and
gamma rays as well as S/M and G2/M checkpoint con-
trols. This mutation did not sensitize ES cells to DNA-
damaging agents (Figure 8A), nor lead to S/M or G2/M
checkpoint deﬁciency (Figure 8B and C), suggesting that
the overall structural integrity of hRad9 is not aﬀected by
the S160A mutation, and that hRad9 plays a role in MMR
speciﬁcally via the hRad9–hMLH1 interaction.
DISCUSSION
hRad9 is critical for cell cycle checkpoint control (17,58)
and for HR repair (40) and base-pair excision repair
(35,38). In this study we have shown that hRad9 directly
interacts with hMLH1 (Figures 1 and 2), and this interac-
tion is important for DNA MMR (Figures 4, 6 and 7).
Recent studies have shown that mismatch proteins func-
tion as sensors for cell cycle checkpoint controls.
Mismatch protein MSH2 (MutS homolog 2) can interact
with ATR, and MutSalpha and MutLalpha are required
to activate ATR to phosphorylate Chk1 and promote cell
cycle checkpoint control in response to MNNG-caused
DNA methylation damage (59,60). This study shows
that Rad9 plays an important role in MMR via a direct
Figure 6. mRad9
–/– ES cells are deﬁcient in MMR. (A) Experiments for detecting MMR activity. The reporter plasmid containing a T:G hetero-
duplex mismatch and a control plasmid containing homoduplex T:A in the start codon of EGFP were transfected into cells to measure MMR
activity. MMR-mediated repair of T:G to T:A restored the starting codon and thus EGFP expression. Control plasmid containing intact mRFP-C1
sequence was co-transfected into the cells to monitor transfection eﬃciency. HCT116 cells were used as the MMR-negative control and HCT116 cells
transfected with pZeoSV2-hMLH1 as the positive control; only a small population of HCT116 cells transfected with the reporter plasmid containing
the T:G heteroduplex appeared in the lower-right and upper-right regions (EGFP-positive) and a signiﬁcant portion of the same cells co-transfected
with pZeoSV2-hMLH1 were located in the lower-right and upper-right regions. This MMR activity detection system was applied to monitor MMR
activities of ES cells with and without Rad9. The cells containing Rad9 were signiﬁcantly more eﬃcient in repairing T:G into T:A than cells without
Rad9. (B) Relative EGFP expressions of HCT116, HCT116+hMLH1 after co-transfection of nicked homo- or hetero-duplex EGFP plasmid and
RFP plasmid (pmRFP-C1), derived from three independent experiments described in (A). The relative EGFP expression levels were calculated using
a method developed by Lei et al. (32) and reﬂected MMR activities of these cells. (C) Relative EGFP expressions of mRad9
+/+, mRad9
–/–, mRad9
–/–
+ hRad9 and mRad9
–/– + mRad9 cells, derived from three independent experiments as described in (A).
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signaling ﬂow from cell cycle checkpoint via checkpoint
protein Rad9 toward mismatch repair is currently unclear.
The current prevailing view is that hRad9, hRad1 and
hHus1 form a PCNA-like ring structure, the 9-1-1 com-
plex (6–11), and in this heterotrimer form function in cell
cycle checkpoint control and DNA repair (61,62). PCNA
itself can also interact with hMLH1 and play a role in 30 to
50 excision in MMR (22). However, unlike either hRad 1
or hHus1, hRad9 is able to immunoprecipitate hMLH1
(Figure 3). This implies that hRad9’s function in MMR is
not in the 9-1-1 complex form. A hRad9 mutant that
contains point mutations that aﬀect interactions with
hHus1 and/or hRad1 would be useful to further clarify
if hRad9 plays a role in MMS independent of the 9-1-1
complex.
hRad9 has been reported to possess 30 to 50 nuclease
activity (63) and this feature of hRad9 is compatible
with its role in MMR. Four redundant exonucleases
(I, VII, X and RecJ) have been identiﬁed in Escherichia
coli MMR (19), whereas only ExoI has been experimen-
tally implicated as an MMR-associated 50-directed exonu-
clease in eukaryotic cells (26,64). The eﬀects of ExoI
deﬁciency on MMR in both yeast and mice are moderate
compared to those of Msh2 or Mlh1, and this suggests the
existence of more functionally redundant exonucleases in
these organisms (26,64). Recent studies have shown that
regulatory factor X (RFX) and MRE11 play roles in
MMR. RFX stimulates mismatch-dependent 50 to 30 exci-
sion activity (27), and MRE11 possesses mismatch-
dependent 30 to 50 excision activity (65). Since hRad9
has 30 to 50 nuclease activity (63), hRad9 is likely to also
function in mismatch-dependent 30 to 50 excision.
However, the 30 to 50 nuclease activity of hRad9 is
weaker than would be expected if hRad9’s 30 to 50 nuclease
activity is important in MMR. We cannot exclude the
possibility that hRad9 may function in MMR through
the other unknown ways. Nevertheless, this hypothesis
that hRad9 plays a role in MMR-dependent 30 to 50 nucle-
ase activity merits future experimental studies.
The Rad9–MLH1 interaction might be a hot spot for
mutation in tumor cells. The hMLH1 mutation leads to
hereditary nonpolyposis colorectal cancer (HNPCC) and
various other types of tumor (66–69). Mice with an mRad9
deletion in skin keratinocytes are susceptible to developing
skin tumors (70). The deletion of mRad9 in all cell types
causes mouse embryonic lethality, possibly due to the loss
of its many important functions including cell cycle check-
point control, base-excision repair and DNA double-
strand break repair. In this study, we have shown that
the Ser160Ala mutation of hRad9 leads to drastic reduc-
tion of the hRad9–hMLH1 interaction and MMR activity
(Figures 4 and 6), but has no impact on cell cycle check-
point control and cellular sensitivity to gamma rays, UV-
light and DNA replication inhibitorHU. Cells with this
type of mutation may easily survive and possess a mutator
phenotype, thus developing into tumors.
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+/+ ES cells,
mRad9
–/– ES cells and the two mRad9
–/– ES cells that stably express hRad9-WT and hRad9-S160A, respectively. The four types of cells were treated
with mock treatment, 250mM HU for 24h, 10J/m
2 and 6Gy gamma rays, respectively, and then allowed to grow for 10 days to form cell colonies.
The survival level stands for the ratio of the number of colonies formed from treated cells compared with the number of colonies formed from
untreated cells. Results presented are the averages of three independent experiments, and each experimental data point is the average of duplicate cell
samples. (B) The S/M checkpoint. The four types of cells described above were incubated in medium containing 1mM HU for 0, 8 and 12h, and
then prepared for S/M checkpoint analysis by ﬂow cytometry. The mRad9
–/– ES cells stably expressing either hRad9-WT or hRad9-S160A showed
intact S/M checkpoint while mRad9
–/– ES cells containing the empty vector demonstrated prematured chromosome condensation (arrows) after
incubation with HU for 8 or 12h. (C)G 2/M checkpoint. The four types of cells described above were irradiated with 10Gy gamma rays and then
grown for 0, 8 and 12h. mRad9
+/+ ES cells were arrested in the G2/M border 8h after irradiation, and only a small population of the cells from the
last cell cycle moved into the G1 phase 12h after irradiation. mRad9
–/– ES cells were unable to arrest at the G2/M border and moved into the G1
phase (arrow) 8h after irradiation, and cells from the last cell cycle had already moved into the S phase (arrow) 12h after irradiation. To conﬁrm
that the mRad9
–/– ES cells in G1 and S phases 8 and 12h after irradiation were from the last cycle, 50ng/ml colcemid was added to one set of cells to
block cells in the M phase. Indeed, colcemid was able to block the cells in the M phase 8 and 12h after irradiation, suggesting that they came from
the last cell cycle. The mRad9
–/– ES cells stably expressing either hRad9-WT or hRad9-S160A showed intact G2/M checkpoint control. (D) The
diﬀerent cell lines were incubated in serum-free medium containing various concentrations of MNU at 38C for 1h. After rinsing, fresh medium was
added to form colonies, and survival rates were determined. Results presented are the means of three separate experiments performed in duplicate.
(E) The MMS-resistant experiment was carried out in the same way as that in (D).
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